All In Biotech

Drug Trial Radar · NCT03958123

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

Evaluation of the Effects of Multiple Therapeutic and Supratherapeutic Doses of Cebranopadol on Cardiac Repolarization in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jul 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 171 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

171

Actual

Start

Jul 10, 2013

Primary completion

Nov 27, 2013

Study completion Nov 27, 2013

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
Collaborators
Forest Laboratories
First posted
May 21, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this study was to evaluate the effects of cebranopadol (GRT6005) on the electrical activity of the heart in healthy participants. The study consisted of a screening period within 21 days before the first dose of investigational medicinal product (IMP) (between Day -25 and Day -4) during which informed consent was obtained and the general suitability of the participants for the trial was assessed according to the inclusion/exclusion criteria. Participants were confined to the trial site from 4 days before first IMP dosing on Day 1 to 4 days after last IMP dosing on Day 30. During this period, multiple-doses of cebranopadol or matching placebo and a single-dose of moxifloxacin or matching placebo were administered. Moxifloxacin was used as a positive control. It has consistently shown that it has an effect on the heart rhythm. Continuous 12-lead ECGs were recorded at defined time points. Multiple blood and urine samples were drawn for pharmacokinetic evaluations and safety laboratory monitoring (hematology, chemistry, and urinalysis). Additional safety evaluations included recording of adverse events, vital signs (systolic and diastolic blood pressure, pulse rate, respiration rate, body temperature, and weight), oxygen saturation, standard 12-lead ECG, Clinical Opiate Withdrawal Scale (COWS) assessment, and Columbia-Suicide Severity Rating Scale (C-SSRS) assessment. An End-of-Trial Visit was performed on Day 34, or within 7 days after the last pharmacokinetic sample on Day 34, or at early withdrawal.

Conditions

  • Prolonged QTc Interval
  • Pharmacokinetic

Interventions

  • 100 μg cebranopadolDrug

    Encapsulated 100 μg cebranopadol tablet.

  • 200 μg cebranopadolDrug

    Encapsulated 200 μg cebranopadol tablet.

  • 400 μg cebranopadolDrug

    Encapsulated 400 μg cebranopadol tablet.

  • Placebo to cebranopadol encapsulated tabletsDrug

    Matching placebo to cebranopadol encapsulated tablet.

  • 400 mg MoxifloxacinDrug

    Encapsulated 400 mg moxifloxacin tablet.

  • Placebo to moxifloxacin encapsulated tabletsDrug

    Matching placebo to moxifloxacin (400 mg) encapsulated tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. QTcNi change from time-matched baseline measurement on Day -1 to Day 29 - supported sitting positionTime frame: Day -1 up to Day 29

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • US001 Contract research organization

    West Bend, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.